3. A new @jamaoncology.com paper from ACS Professor @drdawnhershman.bsky.social & colleagues reporting patient-reported fatigue was associated w/ inc'd risk of cancer treatment-related toxic effects.
Other ACS-funded authors include Dr. Joe Unger & Dr. Salene Jones.
jamanetwork.com/journals/jam...
Infographic stating Columbia University generates $12.6 billion in economic activity annually in New York, including over $10.7 billion in New York State. The background features a subtle graphic of a torch.
Columbia University's economic activity goes far beyond our campuses.
Explore our contributions to science, technology, the arts, our city, our nation, and the world, since 1754: https://www.columbia.edu/content/tradition-innovation-and-growth
What is your why? This is mine 🥹
🥰
🙌 proud to be part of this #Dreamteam #PayItForward @conquercancer.bsky.social HSR YIA!!!
The Front Line
Our @swog.org group chair's blog:
SWOG at ASCO, 2025
Starting with @drdawnhershman.bsky.social's Karnofsky Science of Oncology Award Lecture in the opening session, the #ASCO25 Annual Meeting will feature some great work by SWOG researchers.
www.swog.org/news-events/...
Who From Oncology is Featured in TIME100 Health 2025?
@drkarenknudsen.bsky.social
@drdawnhershman.bsky.social
oncodaily.com/societies/ti...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TIME100 #Health #TIME100Health
At #ASCO25, @drdawnhershman.bsky.social will be honored with the 2025 David A. Karnofsky Memorial Award for her work in advancing cancer outcomes for all patients. #ASCODailyNews has more on her career & accomplishments: brnw.ch/21wSvbq
Congratulations 🎈
Thank you @nytimes.com for highlighting the impact of federal funding cuts on research & patient care. We share a common mission to improve the lives and wellbeing of others, and we share common values that everyone deserves the best care and treatment opportunities.
www.nytimes.com/2025/03/18/n...
I am profoundly grateful for this extraordinary honor 💗
Incredible accomplishment from our @swog.org 🫁 team. 👏👏👏
So proud of @minasedrakmd for being recognized as a @SusanGKomen rising star 💫-
Better together- very excited about this @swog.org @alliancenctn.org #CTIU collaboration 🤝
The best part of #SABCS24? Lunch with colleagues of course!
Excited to see #PROCTCAE and #GP5 in the inavolisib label! Recurring points in the FDA discussion about needing dose optimization in early drug development to lower doses, maintain efficacy, and improve tolerability. Also comments about needing enrollment of diverse patients. #SABCS24
Super important not to under-treat elderly women - as life expectancy may be quite high!
Thank you all for your advocacy- I would just add - it is not just about measuring pro’s - it’s critically important to mitigate side effects early to help improve tolerance
Such an important topic - so glad #SABCS24 included this in the program. More work needed to figure out how to include #PRO-cTCAE as an endpoint
S2013 and S1501 Reopen for Enrollment with Key Protocol Updates
oncodaily.com/insight/200983
@drdawnhershman.bsky.social
#Cancer #CancerTreatment #Chemotherapy #SWOG #S2013 #ICIBasedTherapy #ImmuneRelatedAdverseEvents #S1501 #OncoDaily #SWOGNCORPResearchBaseTrials #Oncology
This @swog.org success story is only possible with #NCI federally funded research 🤞
Congrats to Dr. Parminder Singh and Dr. Sonam Puri - recipients of our latest career awards supporting outstanding @swog.org research #SWOGonc
cc @moffittnews.bsky.social
thehopefoundation.org/blog/general...
Front Line
Our SWOG Group Chair blog:
Modeling Adverse Event Risk Prediction: S2013 and S1501 Are Reopen to Enrollment!
Two key trials by the SWOG #NCORP Research Base have reopened after temporary closures. Both trials are prime examples of public-powered research!
www.swog.org/news-events/...
Advanced biomarker testing for adults with acute myeloid leukemia or myelodysplastic syndrome
#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH
"Because health insurance has become the face of both the rising premiums and the intrusive cost-containment efforts that are largely delegated to them, they have become the primary target of that anger. But it’s not just insurers," Elliott S. Fisher writes: www.statnews.com/2024/12/05/u...
Congratulations @lynn_hershman for making the Art Review Power 100. 👏👏👏
artreview.com/power-100/
The S2312 trial in #mCRPC asks if adding carboplatin to cabazitaxel will significantly improve radiographic PFS in patients whose tumors are aggressive variant #prostatecancer (AVPC-MS) vs those whose tumors are not.
The S2312 trial in #mCRPC asks if adding carboplatin to cabazitaxel will significantly improve radiographic PFS in patients whose tumors are aggressive variant #prostatecancer (AVPC-MS) vs those whose tumors are not.
PI: Paul Corn, MD, PhD, @mdanderson.bsky.social
swog.org/clinical-trials/S2312
That's a wrap!
Yesterday marked our final funding deadline of the year.
We're busy reviewing, preparing for 2025, and excited for the next big questions we'll help @swog.org members to answer - thank you to our donors who make it all possible! #SWOGonc
Upcoming opportunities:
tinyurl.com/SWOG2025
Adherence is such big issue and such a challenging problem solve - we found the same thing in breast cancer patients taking endocrine therapy @swog.org study #S1105- pubmed.ncbi.nlm.nih.gov/32369401/
Lots of work needed to improve outcomes in patients who need oral therapies!!
